Werewolf Therapeutics Inc
HOWL1.250USD
+0.090+7.72%
Horário de mercado （ET）Cotações atrasadas em 15 min
56.01MValor de mercado
PerdaP/L TTM
Mais detalhes de Werewolf Therapeutics Inc Empresa
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.
Informações da empresa
Código da empresaHOWL
Nome da EmpresaWerewolf Therapeutics Inc
Data de listagemApr 30, 2021
CEODr. Daniel J. (Dan) Hicklin, Ph.D.
Número de funcionários46
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 30
Endereço200 Talcott Avenue
CidadeWATERTOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02472
Telefone16179520555
Sitehttps://werewolftx.com/
Código da empresaHOWL
Data de listagemApr 30, 2021
CEODr. Daniel J. (Dan) Hicklin, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
Dr. Chulani Karunatilake, Ph.D.
Dr. Chulani Karunatilake, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Michael A. (Mike) Sherman
Mr. Michael A. (Mike) Sherman
Independent Director
Independent Director
--
--
Dr. Luke Evnin, Ph.D.
Dr. Luke Evnin, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Randi Isaacs, M.D.
Dr. Randi Isaacs, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 14 de mai
Atualizado em: qua, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RA Capital Management, LP
14.89%
MPM Capital Inc.
9.60%
PFM Health Sciences, LP
5.59%
MPM BioImpact LLC
5.37%
BofA Global Research (US)
4.69%
Other
59.87%
Investidores
Investidores
Proporção
RA Capital Management, LP
14.89%
MPM Capital Inc.
9.60%
PFM Health Sciences, LP
5.59%
MPM BioImpact LLC
5.37%
BofA Global Research (US)
4.69%
Other
59.87%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
19.93%
Venture Capital
14.89%
Hedge Fund
12.83%
Investment Advisor
9.66%
Research Firm
5.33%
Corporation
4.56%
Individual Investor
1.51%
Bank and Trust
0.08%
Family Office
0.02%
Other
31.19%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
157
30.87M
68.80%
-5.72M
2025Q1
159
30.37M
68.02%
-6.24M
2024Q4
157
31.11M
69.81%
-7.22M
2024Q3
161
35.12M
80.23%
-3.46M
2024Q2
148
35.04M
80.49%
-1.98M
2024Q1
150
35.07M
81.79%
+2.03M
2023Q4
134
30.53M
84.54%
+2.78M
2023Q3
139
30.67M
86.21%
+2.11M
2023Q2
142
30.83M
86.75%
+2.42M
2023Q1
141
30.79M
87.31%
+3.80M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RA Capital Management, LP
6.68M
14.89%
+536.43K
+8.73%
May 14, 2025
MPM Capital Inc.
4.31M
9.6%
--
--
Apr 14, 2025
PFM Health Sciences, LP
2.51M
5.59%
-398.94K
-13.73%
Mar 31, 2025
MPM BioImpact LLC
2.41M
5.37%
+20.80K
+0.87%
Mar 31, 2025
BofA Global Research (US)
2.10M
4.69%
+24.27K
+1.17%
Mar 31, 2025
Arkin Bio Ventures LP
2.05M
4.56%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.51M
3.36%
+88.47K
+6.23%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.48M
3.3%
-29.02K
-1.92%
Mar 31, 2025
Rubric Capital Management LP
1.33M
2.97%
--
--
Mar 31, 2025
Millennium Management LLC
784.62K
1.75%
+188.33K
+31.58%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
DFA Dimensional US Core Equity Market ETF
0%
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
Ver Mais
DFA Dimensional US Core Equity Market ETF
Proporção0%
iShares Micro-Cap ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
iShares Russell 2000 Growth ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
